Nanjing First Hospital
Nanjing, Jiangsu, 210001, China
Location status: Recruiting
NCT Number: NCT06937112
Evaluate the safety of the novel FAP targeted molecular probe 18F-FAPI-YQ104 labeled with radioactive isotopes in clinical applications and verify its effectiveness in tumor diagnosis.
Interested in participating?
Request Info18 year–75 year
All sexes
Observational
Nanjing, Jiangsu, 210001, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous injection of 18F-FAPI-YQ104 for PET-CT examination
Time frame: 60 minutes after administration
Contact information is provided by the study sponsor or research team.
Nanjing First Hospital, Nanjing Medical University
Other
Clinical Application of a Novel 18F Labeled Fibroblast Activation Protein (FAP) Targeted Molecular Probe in Early Tumor Diagnosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06632886
Breast Cancer, Breast Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06926075
Adnexal Diseases, Astrocytoma
Kogarah, New South Wales, Australia
View Trial DetailsNCT02374255
Astrocytoma, Cancer of Pancreas
New Haven, Connecticut, United States
View Trial DetailsNCT07038343
Biliary Tract Cancer (BTC), Biliary Tract Diseases
Gilbert, Arizona, United States
View Trial Details